129 related articles for article (PubMed ID: 21510347)
1. [Practical ECG problems in the elderly patient. Case number 16. Moxifloxacin-associated QT interval prolongation].
Farhoumand AD; Trombert V; Eusebio J
Rev Med Suisse; 2011 Mar; 7(286):624-5. PubMed ID: 21510347
[No Abstract] [Full Text] [Related]
2. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
3. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
Stylianou A; Roger J; Stephens K
J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin-induced torsades de pointes.
Sherazi S; DiSalle M; Daubert JP; Shah AH
Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
[TBL] [Abstract][Full Text] [Related]
5. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
[TBL] [Abstract][Full Text] [Related]
6. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
[TBL] [Abstract][Full Text] [Related]
7. Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin.
Couderc JP; McNitt S; Hyrien O; Vaglio M; Xia X; Polonsky S; Moss AJ; Zareba W
Drug Saf; 2008; 31(3):249-60. PubMed ID: 18302449
[TBL] [Abstract][Full Text] [Related]
8. First report of metronidazole-induced QT interval prolongation.
Cohen O; Saar N; Swartzon M; Kliuk-Ben-Bassat O; Justo D
Int J Antimicrob Agents; 2008 Feb; 31(2):180-1. PubMed ID: 18082376
[No Abstract] [Full Text] [Related]
9. Moxifloxacin associated vanishing bile duct syndrome.
Robinson W; Habr F; Manlolo J; Bhattacharya B
J Clin Gastroenterol; 2010 Jan; 44(1):72-3. PubMed ID: 19581811
[No Abstract] [Full Text] [Related]
10. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
[TBL] [Abstract][Full Text] [Related]
11. Vardenafil-associated QTc changes: not merely a normal autonomic process.
Barbey JT
Clin Pharmacol Ther; 2012 Apr; 91(4):580; author reply 580-1. PubMed ID: 22378160
[No Abstract] [Full Text] [Related]
12. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.
Bloomfield DM; Kost JT; Ghosh K; Hreniuk D; Hickey LA; Guitierrez MJ; Gottesdiener K; Wagner JA
Clin Pharmacol Ther; 2008 Oct; 84(4):475-80. PubMed ID: 19238652
[TBL] [Abstract][Full Text] [Related]
13. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
14. Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies.
Fosser C; Duczynski G; Agin M; Wicker P; Darpo B
Clin Pharmacol Ther; 2009 Nov; 86(5):503-6. PubMed ID: 19339965
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin and torsade de pointes.
Dale KM; Lertsburapa K; Kluger J; White CM
Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
[TBL] [Abstract][Full Text] [Related]
16. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?
Darpo B; Agin M; Kazierad DJ; Layton G; Muirhead G; Gray P; Jorkasky DK
J Clin Pharmacol; 2006 Jun; 46(6):598-612. PubMed ID: 16707406
[TBL] [Abstract][Full Text] [Related]
17. Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
Grosjean P; Urien S
J Clin Pharmacol; 2012 Mar; 52(3):329-38. PubMed ID: 21415283
[TBL] [Abstract][Full Text] [Related]
18. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
[TBL] [Abstract][Full Text] [Related]
19. Electrocardiographic method for identifying drug-induced repolarization abnormalities associated with a reduction of the rapidly activating delayed rectifier potassium current.
Couderc JP; Vaglio M; Xia X; McNitt S; Hyrien O
Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():4010-5. PubMed ID: 17946595
[TBL] [Abstract][Full Text] [Related]
20. No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Sturm S; Bentley D; Jordan P; Russell-Yarde F; Ruf T
J Cardiovasc Pharmacol; 2012 Mar; 59(3):288-97. PubMed ID: 22113345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
